Loratadine-d5

Loratadine-d5 is the deuterium labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-dengue-virus (DENV) activity. Loratadine can inhibit immunologic release of inflammatory mediators.

Product Specifications

CAS Number

[1398065-63-8]

Product Name Alternative

Loratidine-d5; SCH 29851-d5

UNSPSC

12352005

Hazard Statement

H410

Target

Histamine Receptor; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Others

Field of Research

Infection; Endocrinology; Inflammation/Immunology

Purity

99.96

Solubility

DMSO : 50 mg/mL (ultrasonic; warming)

Smiles

ClC1=CC=C(/C(C2=NC=CC=C2CC3)=C4CCN(CC/4)C(OC([2H])([2H])C([2H])([2H])[2H])=O)C3=C1

Molecular Formula

C22H18D5ClN2O2

Molecular Weight

387.91

Precautions

H410

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Kay GG, Harris AG. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin Exp Allergy. 1999 Jul;29 Suppl 3:147-50.; Menardo JL, Horak F, Danzig MR, Czarlewski W. A review of loratadine in the treatment of patients with allergic bronchial asthma. Clin Ther. 1997 Nov-Dec;19 (6) :1278-93; discussion 1523-4.; Monroe EW. Loratadine in the treatment of urticaria. Clin Ther. 1997 Mar-Apr;19 (2) :232-42.; Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994 Oct;48 (4) :617-37.; Roman IJ, Danzig MR. Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. Clin Rev Allergy. 1993 Spring;11 (1) :89-110.; Shahen M, et al. Dengue virus causes changes of MicroRNA-genes regulatory network revealing potential targets for antiviral drugs. BMC Syst Biol. 2018 Jan 4;12 (1) :2.; Kleine-Tebbe J, et al. Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allergy Clin Immunol. 1994;93 (2) :494-500.